{"raw_mentions": "Here are the extracted sentences:\n\nThe antibody had a binding affinity (EC50) of about 4 ng/mL for NKG2A+ cells (K<sub>D</sub>\u02dc4 ng/mL).\nThe K<sub>D </sub>for full receptor occupancy (the EC100) was about 100 ng/ml.\nThe EC50 concentration (the amount that provides a 50% of maximum) in the CD107 mobilization assay was determined to be about 400 ng/ml, and the EC100 was about 10,000 ng/ml (10 \u03bcg/ml).\nThe dose of 4 mg/kg provided an initial (peak) blood concentration of about 100 \u03bcg/ml, i.e. at about the EC<sub>100 </sub>for efficacy in tissues, and a continued (minimum) blood concentration above 30 \u03bcg/ml up to the two week time point, or, as of the fourth dose a continued (minimum) blood concentration of approximately 100 \u03bcg/ml.\nThe dose of 10 mg/kg provided a continued (minimum) blood concentration approximately 100 \u03bcg/ml."}
{"final_json": [{"molecule_name": null, "protein_target_name": "NKG2A", "binding_metric": "EC50", "value": "4", "unit": "ng/mL", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "K_D", "value": "4", "unit": "ng/mL", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "EC100", "value": "100", "unit": "ng/ml", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "EC50", "value": "400", "unit": "ng/ml", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "EC100", "value": "10000", "unit": "ng/ml", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "EC100", "value": "10", "unit": "\u03bcg/ml", "is_logarithmic": false}]}
{"raw_mentions": "There are no sentences in the provided text that contain all four required components: a specific molecule name, ID or other identifier, a bioactivity metric, a specific numeric value for that metric, and a unit for that value. The text appears to be a descriptive passage about immunoglobulins, antibodies, and their properties, but it does not include specific data or measurements that meet the specified criteria."}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nAn anti-NKG2A antibody can advantageously bind to an extracellular portion of NKG2A with a KD that is at least 100 fold lower than the KD for binding to NKG2C.\nThe antibody can for example have an EC50 for binding (high affinity) to NKG2A-expressing cells of between 0.5-10 ng/ml, optionally 1-5 ng/ml, optionally 1-10 ng/ml, optionally 1-20 ng/ml, e.g. about 4 ng/ml."}
{"final_json": [{"molecule_name": "anti-NKG2A antibody", "protein_target_name": "NKG2A", "binding_metric": "KD", "value": "<100 fold lower than the KD for binding to NKG2C", "unit": null, "is_logarithmic": false}, {"molecule_name": "anti-NKG2A antibody", "protein_target_name": "NKG2A", "binding_metric": "EC50", "value": "0.5-10 ng/ml", "unit": "ng/ml", "is_logarithmic": false}, {"molecule_name": "anti-NKG2A antibody", "protein_target_name": "NKG2A", "binding_metric": "EC50", "value": "1-5 ng/ml", "unit": "ng/ml", "is_logarithmic": false}, {"molecule_name": "anti-NKG2A antibody", "protein_target_name": "NKG2A", "binding_metric": "EC50", "value": "1-10 ng/ml", "unit": "ng/ml", "is_logarithmic": false}, {"molecule_name": "anti-NKG2A antibody", "protein_target_name": "NKG2A", "binding_metric": "EC50", "value": "1-20 ng/ml", "unit": "ng/ml", "is_logarithmic": false}, {"molecule_name": "anti-NKG2A antibody", "protein_target_name": "NKG2A", "binding_metric": "EC50", "value": "about 4 ng/ml", "unit": "ng/ml", "is_logarithmic": false}]}
{"raw_mentions": "There are no sentences that meet the specified criteria. The text does not contain specific molecule names, bioactivity metrics, numeric values, and units as required."}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nThe antibody had a binding affinity (EC50) of about 4 ng/mL for NKG2A+ cells (K<sub>D</sub>\u02dc4 ng/mL).\nThe K<sub>D </sub>for full receptor occupancy (the EC100) was about 100 ng/ml."}
{"final_json": [{"molecule_name": "antibody", "protein_target_name": "NKG2A", "binding_metric": "EC50", "value": "4", "unit": "ng/mL", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": "NKG2A", "binding_metric": "Kd", "value": "4", "unit": "ng/mL", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "EC100", "value": "100", "unit": "ng/ml", "is_logarithmic": false}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* A sigmoid Emax model was used to fit the plasma concentration-effect relationship, with an EC50, defined as the serum drug concentration to reach 50% of Emax, i.e. 50% of NKG2A occupancy here for IPH2201.\n* Results of modelling are shown in FIG, substantially complete (at least 90%) receptor saturation of NKG2A+ cells can be achieved by administering 0.03 mg/kg every two weeks for IPH2201.\n* A dose of 0.1 mg/kg can be administered every four weeks to maintain substantially complete saturation of NKG2A for IPH2201.\n* If saturation in the extravascular tissue (e.g, a solid tumor) is desired, an approximately 10-fold higher dose is believed to be needed, translating to a dose of about 0.4 mg/kg every two weeks, 1 mg/kg every four weeks for IPH2201.\n* The results for saturation of NKG2A receptors from this human clinical trial was consistent with the in concentration of anti-NKG2A required for full receptor occupancy (the EC100) determined in vitro (see Example 4) for IPH2201."}
{"final_json": [{"molecule_name": "IPH2201", "protein_target_name": "NKG2A", "binding_metric": null, "value": "50%", "unit": "%", "is_logarithmic": false}, {"molecule_name": "IPH2201", "protein_target_name": "NKG2A", "binding_metric": null, "value": "0.03", "unit": "mg/kg", "is_logarithmic": false}, {"molecule_name": "IPH2201", "protein_target_name": "NKG2A", "binding_metric": null, "value": "0.1", "unit": "mg/kg", "is_logarithmic": false}, {"molecule_name": "IPH2201", "protein_target_name": "NKG2A", "binding_metric": null, "value": "0.4", "unit": "mg/kg", "is_logarithmic": false}, {"molecule_name": "IPH2201", "protein_target_name": "NKG2A", "binding_metric": null, "value": "1", "unit": "mg/kg", "is_logarithmic": false}, {"molecule_name": "IPH2201", "protein_target_name": "NKG2A", "binding_metric": "EC100", "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": "IPH2201", "protein_target_name": "NKG2A", "binding_metric": "EC50", "value": null, "unit": null, "is_logarithmic": false}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n1. The 0.01 \u03bcg/mL (10 ng/mL) dose is approximatively at the EC50 of the cetuximab effect.\n2. Anti-NKG2A antibody whose heavy chain amino acid sequence is shown in SEQ ID NO: 3 and whose light chain amino acid sequence is shown in SEQ ID NO: 7 was used at a final concentration of 10 \u03bcg/mL corresponding to full functional activity, and EGFR inhibitor cetuximab was used at two suboptimal doses of 0.001 \u03bcg/mL or 0.01 \u03bcg/mL.\n3. Cetuximab was used at two suboptimal doses of 0.001 \u03bcg/mL and 0.01 \u03bcg/mL (\u02dcEC50) and at a saturating dose of 0.1 \u03bcg/mL in these experimental settings.\n4. Cetuximab was tested at a dose response, 1/10 serial dilution starting at 10 \u03bcg/mL."}
{"final_json": [{"molecule_name": "cetuximab", "protein_target_name": null, "binding_metric": "EC50", "value": "0.01", "unit": "\u03bcg/mL", "is_logarithmic": false}, {"molecule_name": "cetuximab", "protein_target_name": "EGFR", "binding_metric": null, "value": "0.01", "unit": "\u03bcg/mL", "is_logarithmic": false}, {"molecule_name": "cetuximab", "protein_target_name": null, "binding_metric": "EC50", "value": "0.01", "unit": "\u03bcg/mL", "is_logarithmic": false}, {"molecule_name": "cetuximab", "protein_target_name": null, "binding_metric": null, "value": "10", "unit": "\u03bcg/mL", "is_logarithmic": false}]}
